ADHD and Hypermobility / EDS: What the Emerging Evidence Suggests

The clinical observation that ADHD, autism and joint hypermobility seem to cluster together has been around for some years and has begun to attract serious research attention. The evidence base is still emerging rather than mature, and it is worth being clear about what is and is not established. This article covers what the current research shows about ADHD and hypermobility spectrum conditions (including hypermobile Ehlers-Danlos syndrome), where the gaps are, and what this means in practice for adults working through the picture.

What hypermobility and EDS are

Joint hypermobility means joints that move beyond the normal range of motion. Generalised joint hypermobility is common in the general population (around 10 to 20 percent depending on measurement). Hypermobility on its own, without symptoms, is not a medical problem.

Hypermobility spectrum disorders (HSD) and the Ehlers-Danlos syndromes (EDS) are a group of connective tissue conditions where hypermobility is associated with other features such as pain, joint instability, fatigue, and sometimes skin and cardiovascular involvement ^{[3, 4]}. Hypermobile Ehlers-Danlos syndrome (hEDS) is the most common subtype and is diagnosed clinically using the 2017 international diagnostic criteria ^[3]. The thirteen recognised EDS subtypes are mostly rare; hEDS is the only common one.

Diagnosis of HSD or hEDS is made by a clinician with specific training, often a rheumatologist or specialist in connective tissue conditions. NHS access varies; many UK adults seek private assessment.

What the evidence on the link with ADHD shows

The strongest recent UK contribution is the 2022 Csecs et al. paper in Frontiers in Psychiatry ^[1]. The study examined a large clinical sample and found:

• Joint hypermobility was significantly more common in adults with ADHD, autism or both than in matched comparison samples
• Among adults with ADHD, around half met criteria for generalised joint hypermobility
• The hypermobile group also showed higher rates of dysautonomic symptoms (orthostatic intolerance, palpitations, gastrointestinal symptoms) and chronic pain

The 2016 Cederlöf et al. Swedish national cohort study used population registry data of over 1,700 people with an EDS or hypermobility syndrome diagnosis and compared rates of psychiatric conditions ^[2]. ADHD was significantly more common in the EDS / hypermobility group than in the general population, as were autism, anxiety and depression.

Smaller observational studies have reported similar patterns. The convergence across studies suggests a real association rather than a sampling artefact.

The mechanisms are not yet well understood. Plausible candidates include shared developmental biology, dysautonomic contributions to ADHD-like symptoms (poor concentration, fatigue, brain fog driven by autonomic dysregulation), and shared connective tissue biology affecting neuronal function. None of these has been established as the explanation.

Where the gaps are

A few honest limitations are worth flagging:

• Most of the evidence is observational and cross-sectional. Longitudinal and prospective studies are scarce.
• The diagnostic criteria for hEDS are themselves contested and have been refined repeatedly. Studies using older criteria may not be directly comparable with current practice.
• Causality is unclear in both directions. ADHD does not cause hypermobility; hypermobility does not straightforwardly cause ADHD. The likely picture is shared underlying biology, but this is not established.
• Self-report studies may over-estimate the association because patients with one condition are more likely to be aware of and report symptoms of the other.

The honest position is that the association is now reasonably well documented, but the underlying mechanism is still being worked out, and the clinical implications are still being defined.

What this means in practice

For adults with ADHD or autism who also have hypermobility, several practical points apply:

The fatigue and pain are real

The literature confirms that the chronic pain, fatigue and dysautonomic symptoms reported by patients in this group are not invented or exaggerated. They are part of the picture and warrant proper assessment and management.

Standard ADHD assessment still applies

The presence of hypermobility or hEDS does not change the standard NICE NG87 pathway for ADHD assessment and treatment ^[5]. ADHD is assessed and treated using the usual approach. NeuroFX offers private adult ADHD assessment, including a private adult ADHD assessment for women pathway where the female presentation is in the picture, with co-occurring physical conditions considered as part of the broader clinical work.

Stimulant medication and cardiovascular considerations

Where hEDS or HSD is associated with postural orthostatic tachycardia syndrome (POTS) or other dysautonomic features, stimulant medication prescribing decisions consider these carefully. Stimulants can worsen tachycardia and may need to be paired with cardiology or POTS-clinic input. This is specialist territory and is part of a properly run prescribing pathway.

Connective tissue assessment may be useful

For adults with the ADHD or autism picture and clear hypermobility-related symptoms (chronic pain, joint instability, marked fatigue), assessment by a rheumatologist or specialist in connective tissue conditions can clarify whether HSD or hEDS criteria are met and open access to appropriate physiotherapy and pain management input.

Be cautious of confident causal claims

The relationship is real but the mechanism is not established. Be wary of online sources or practitioners who make strong causal claims in either direction or who position specific supplements or interventions as the answer to the combination.

What this means in practice (the short version)

• Hypermobility and ADHD co-occur far above chance. Around half of adults with ADHD in clinical samples show generalised joint hypermobility.
• The Csecs 2022 UK study and the Cederlöf 2016 Swedish registry study are the strongest available evidence; both show significant associations.
• The mechanism is not established. Causal claims should be treated with caution.
• Standard ADHD assessment and NICE NG87 treatment apply; stimulant prescribing considers any dysautonomic features.
• Connective tissue assessment is appropriate where hypermobility-related symptoms are clinically significant.

When to speak to a professional

Speak to your GP if you have hypermobility-related symptoms (chronic pain, joint instability, marked fatigue, dysautonomic features) alongside ADHD or autism. NHS routes for ADHD assessment are well established; access to specialist connective tissue assessment varies and may involve private referral. Ehlers-Danlos Support UK has resources on finding specialists. Seek urgent help via 111, 999 or A&E for any acute medical or mental health crisis.

Sources

1. Csecs JLL, Iodice V, Rae CL, et al. Joint Hypermobility Links Neurodivergence to Dysautonomia and Pain. Frontiers in Psychiatry. 2022;12:786916.
2. Cederlöf M, Larsson H, Lichtenstein P, et al. Nationwide population-based cohort study of psychiatric disorders in individuals with Ehlers-Danlos syndrome or hypermobility syndrome. BMC Psychiatry. 2016;16:207.
3. Malfait F, Francomano C, Byers P, et al. The 2017 international classification of the Ehlers-Danlos syndromes. American Journal of Medical Genetics Part C: Seminars in Medical Genetics. 2017;175(1):8-26.
4. Ehlers-Danlos Support UK. About Ehlers-Danlos syndromes. https://www.ehlers-danlos.org/
5. NICE. Attention deficit hyperactivity disorder: diagnosis and management. NG87. National Institute for Health and Care Excellence. https://www.nice.org.uk/guidance/ng87